- Identification of Schistosoma haematobium and Schistosoma mansoni linear B-cell epitopes with 1
- diagnostic potential using *in silico* immunoinformatic tools and peptide microarray technology. 2
- Short title: Schistosoma haematobium and Schistosoma mansoni B-cell epitopes. 3
- Arthur Vengesai<sup>1\*</sup>, Marble Manuwa<sup>2</sup>, Herald Midzi<sup>3</sup>, Masimba Mandeya<sup>1</sup>, Victor Muleva<sup>1</sup>, Keith 4
- Mujeni<sup>1</sup>, Isaac Chipako<sup>1</sup>, Dean Goldring<sup>4</sup>, Takafira Mduluza<sup>2</sup> 5
- <sup>1</sup>Department of Biochemistry, Faculty of Medicine and Health Sciences, Midlands State University, 6
- 7 Senga Road, Gweru, Zimbabwe.
- <sup>2</sup>Department of Biotechnology and Biochemistry, Faculty of Science, University of Zimbabwe, P.O. 8
- 9 Box MP 167, Mt Pleasant, Harare, Zimbabwe.
- <sup>3</sup>Department of Applied Biosciences and Biotechnology, Faculty of Science, Midlands State 10
- University, Senga Road, Gweru, Zimbabwe. 11
- 12 <sup>4</sup>Department of Biochemistry, University of KwaZulu-Natal, P.B. X01, Carbis Road, Scottsville 3209,
- South Africa. 13
- 14
- \*Corresponding author 15
- E-mail : arthurvengesai@gmail.com (AV) 16
- 17

18

- 19
- 20
- 21

22

- 23
- 24
- 25
- 26

27

NOTE: This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice.

#### Abstract 28

#### Introduction 29

30 Immunoinformatic tools can be used to predict schistosome-specific B-cell epitopes with little sequence identity to human proteins and antigens other than the target. This study reports an approach 31 for identifying schistosome peptides mimicking linear B-cell epitopes using in-silico tools and peptide 32

microarray immunoassays validation. 33

#### Method 34

Firstly, a comprehensive literature search was conducted to obtain published schistosome-specific 35 peptides and recombinant proteins with the best overall diagnostic performances. For novel peptides, 36 linear B-cell epitopes were predicted from target recombinant proteins using ABCpred, Bcepred and 37 BepiPred 2.0 in-silico tools. Together with the published peptides, predicted peptides with the highest 38 39 probability of being B-cell epitopes and the lowest sequence identity with proteins from human and other pathogens were selected. Antibodies against the peptides were measured in sera, using peptide 40 microarray immunoassays. Area under the ROC curve was calculated to assess the overall diagnostic 41 performances of the peptides. 42

#### 43 Results

44 Peptide AA81008-19-30 had excellent and acceptable diagnostic performances for discriminating S. mansoni and S. haematobium positives from healthy controls with AUC values of 0.8043 and 0.7326 45 respectively for IgG. Peptides MS3 10186-123-131, MS3 10385-339-354, SmSPI-177-193, SmSPI-46 379-388, MS3-10186-40-49 and SmS-197-214 had acceptable diagnostic performances for 47 discriminating S. mansoni positives from healthy controls with AUC values ranging from 0.7098 to 48 0.7763 for IgG. Peptides SmSPI-359-372, Smp126160-438-452 and MS3 10186-25-41 had acceptable 49 diagnostic performances for discriminating S. mansoni positives from S. mansoni negatives with AUC 50 values of 0.7124, 0.7156 and 0.7115 respectively for IgG. Peptide MS3-10186-40-49 had an 51 acceptable diagnostic performance for discriminating S. mansoni positives from healthy controls with 52 an AUC value of 0.7413 for IgM. 53

#### 54 Conclusion

One peptide with a good diagnostic performance and 9 peptides with acceptable diagnostic 55 performances were identified using the immunoinformatic approach and peptide microarray 56 validation. There is need for evaluation with true negatives and a good reference. 57

Keywords: Schistosoma haematobium, Schistosoma mansoni, peptides, diagnosis, immunoassays, 58 bioinformatics, immunoinformatic tools 59

- 60
- 61
- 62
- 63
- 64
- 65
- 66

#### **1** Author summary

Schistosomiasis commonly known as bilharzia is the third most significant tropical disease after malaria and soil-transmitted helminthiases. Like other neglected tropical diseases common in Zimbabwe, schistosomiasis remains mostly undiagnosed or undetected. This is partly due to the fact that reliable identification of parasites requires expertise for specimen preparation, and microscopic examination which are largely unavailable in most rural clinics. This limitation is further compounded by the fact that the recommended microscopy-based methods for schistosomiasis diagnosis lack sensitivity, especially in infections of low intensity. To overcome some of the caveats associated with microscopy-based methods, highly sensitive serological tests have been utilized. Unfortunately, currently available serological tests have low specificity and show cross-reactivity with other helminthic infections. One way to mitigate the cross-reactivity challenge and increase the specificity, is to use immunoinformatic tools and immunoassays to identify schistosomiasis species-specific immunogenic peptides mimicking B-cell epitopes (short amino acid sequences of the antigen that reacts with antibodies). Utilizing immunoinformatic tools coupled with peptide microarray immunoassay validation approach several peptides that can be used to develop diagnostic tools for showing exposure to infection for people living in non-endemic or low-transmission areas were identified in the current study. 

## 95 **2 Introduction**

Schistosomiasis is a neglected tropical disease caused by blood flukes from the genus Schistosoma 96 97 (1). Zimbabwe is endemic to urogenital schistosomiasis caused by Schistosoma haematobium and intestinal schistosomiasis caused by Schistosoma mansoni (2-4). Besides effective implementation of 98 mass drug administration (MDA) campaigns, access to safe water, improved sanitation and snail 99 control, diagnostic tests are important tools for achieving and sustaining schistosomiasis elimination 100 (1,5,6). Diagnostic tests are important for schistosomiasis surveillance and control. They play a vital 101 role in guiding the distribution of current program resources and the implementation and evaluation of 102 103 schistosomiasis intervention strategies (5,6).

The recommended method for schistosomiasis diagnosis is the detection of schistosome-specific eggs in stool or urine specimens by microscopy. For urogenital schistosomiasis, the urine filtration technique is the standard diagnostic method and for intestinal schistosomiasis, the Kato Katz technique is the standard diagnostic method (6–8). In addition to high specificity (7,9), both techniques have minimal operational costs (the test kits are inexpensive), low complexity and they are relatively easy to perform in resource-limited field settings (6,8,9). Moreover, prepared Kato Katz slides can be stored for months at room temperature for later microscopic examination.

Nevertheless, both techniques have significant disadvantages including, the need for qualified 111 112 personnel to prepare and examine slides, poor reproducibility and most importantly low sensitivity (7,8,10,11). The sensitivity of the techniques is limited by the host infection intensity, daily variation 113 of schistosome egg excretion and uneven distribution of eggs within stool specimens (11). 114 Additionally, both methods are unable to diagnose recent infections (for instance, in cases where 115 worms have not vet started to produce eggs) or single worm/sex infections and the Kato Katz technique 116 is unable to analyse watery stool specimens (9). The lack of sensitivity especially in low endemic areas 117 and after successful control interventions lead to underestimation of true schistosomiasis prevalence 118

in such settings (7–10). Moreover, undetected and untreated individuals may continue schistosomiasis
transmission by contaminating fresh water sources with urine and faeces containing schistosome eggs
(1,9). Due to the numerous disadvantages associated with the microscope based techniques, the use of
other methods like molecular detection, circulating cathodic antigen (CCA), circulating anodic antigen
(CAA) has gathered pace (8). These alternative methods for schistosomiasis diagnosis have their own
advantages and limitations too.

Molecular methods targeting DNA of the parasite are more sensitive and specific and can detect early 125 stage schistosome infections (8). However, molecular methods require skilled laboratory personnel, 126 expensive and fragile equipment and they are time consuming, thus impeding their use as point-of-127 care tools (POC) in remote resource-limited endemic areas (5). Although CCA and CAA allow for 128 rapid schistosomiasis diagnosis, these methods have their own shortcomings (3,7,8). The CCA test is 129 sensitive for moderate to high level S. mansoni infections but not for S. haematobium infections, and 130 its widespread use in poor rural endemic areas may be limited by its cost, currently around US \$1.75 131 132 per test (3,12,13). While the CAA test is more sensitive than the CCA, it is labour intensive and riddled with a complicated assay procedure. This major drawback is further compounded by the fact that there 133 has not been any commercially available CAA tests to date (8). 134

To overcome some of the drawbacks associated with microscopy, molecular, CCA and CAA based 135 diagnostic tests; serological tests have been utilized (14). The use of serological tests has gained 136 137 traction due to higher sensitivities compared to microscopy based techniques (8). However, currently available serological tests exhibit low specificity and are laden with cross-reactivity issues with other 138 helminthic infections due to shared antigenic epitopes (14,15). One way to mitigate the cross-139 reactivity challenge and increase specificity is to use bioinformatic and proteomics tools to predict 140 schistosome specific immunodominant B-cell epitopes with little or no sequence identity to proteins 141 other than the target (4,14,16). However, to date, only a limited number of linear B-cell epitopes have 142 been identified for the serological diagnosis of S. haematobium and S. mansoni (17–19). It is against 143

this background that we present an approach for predicting schistosome specific peptides mimicking linear B-cell epitopes using *in-silico* tools and peptide microarray technology. Several methods can be used for the identification and prediction of linear B-cell epitopes. As previously described, two methods *in-silico* prediction and identification of published peptides reduce the burden and costs associated with epitope mapping by decreasing the list of potential targets for experimental testing (20–24). Therefore, in the present study a comprehensive literature search was conducted to identify published schistosome-specific peptides for inclusion in the peptide microarray immunoassays.

## 151 **3 Methods**

### 152 **3.1 Ethical approval**

Approval to conduct the study was obtained from Medical Research Council of Zimbabwe (MRCZ/A/2571). Provincial Medical directors, District Medical officers, councillors, and headmen provided the permission to carry out the study in the districts. Before enrolment, the aims and procedures of the study were explained to all participants and their parents or guardians in English or Shona. Consent forms were supplied to the children's parents or guardians for signing. Enrolment into the study was completely voluntary and parent or guardians were free to withdraw their children at any time with no need of explanation.

#### 160 **3.2** Study area and population

161 Children living in schistosomiasis endemic areas were purposively selected for the cross-sectional 162 study. The children were permanent residents of Mount Darwin and Shamva rural districts located in 163 Mashonaland central (31°40′0" E longitude and 17°10′0" S latitude) Northeast of Zimbabwe. Negative 164 control sera were obtained from *Schistosoma* microscopy negative individuals without history of 165 exposure or contact with *Schistosoma* contaminated water. These negative control sera were obtained 166 from permanent residents of Glaudina a high density urban area located in Harare the capital city of 167 Zimbabwe.

#### 168 **3.3 Blood collection**

Experienced local nurses collected approximately 5 ml of venous blood for the peptide microarray serological assays from each participant. The 5ml blood limit was within the guidelines for children issued by Medical Research Council of Zimbabwe research ethics committee.

172 3.4 Parasitology examination

Urine and stool specimens were collected between 10:00 am and 14:00 pm for optimal egg passage necessary for diagnosis of schistosomiasis. The specimens were stored away from direct sunlight until processing. The urine filtration technique was used in the diagnosis of *S. haematobium*. This was repeated for three consecutive days to avoid misdiagnosis due to day-to-day egg variation. *S. mansoni* was diagnosed using the Kato Katz method and the formal ether concentration technique to improve accuracy. Participants were classified as infected if at least one parasitic egg was detected.

## 179 **3.5** Peptide selection and *in silico* prediction.

Two methods were used for the identification and prediction of linear B-cell epitopes (peptides). These 180 were a comprehensive literature search for published synthetic peptides (25) and *in silico* prediction 181 182 of novel peptides. For novel peptides, a systematic scoping review (25) was conducted to identify recombinant proteins with the best overall diagnostic performance with different serological assays 183 including protein microarray, ELISA and POC immunochromatographic tests for S. haematobium and 184 S. mansoni. The sequences and the alpha fold predicted structures of the identified recombinant 185 proteins were obtained from Uniprot. SignalP 6.0 was used to identify the presence of signal peptides. 186 Transmembrane domains were predicted using SOSUI and cellular localisation was predicted using 187 WoLF Psort II. DeepView/Swiss-PDB Viewer (www.expasy.org/spdbv/) was used for spatial location 188 of the candidate peptides on the recombinant protein crystal structures. 189

Linear B cell epitopes were predicted using three different programs namely ABCpred, Bcepred and
 BepiPred 2.0. ABCpred uses artificial neural network, Bcepred predicts using physico-chemical
 properties of amino acids and BepiPred 2.0 uses a random forest algorithm. Peptides with the lowest

193 sequence identity with human protein and proteins from other human pathogens were then selected 194 using the NCBI Protein BLAST to minimize cross reactivity. Peptides that had the highest probability 195 of being B-cell epitopes and the lowest sequence identity with proteins from human and other 196 pathogens were selected for inclusion on the peptide microarrays.

197 **3.6** Peptide microarray content

The peptide microarrays were fabricated by PEPperPRINT GmbH (Heidelberg, Germany). The peptide microarrays contained 16 identical sub-arrays (copies). Each sub-array contained 122 *S. haematobium* and *S. mansoni* 9-16 amino acids long peptides printed randomly in duplicate. The peptides on each subarray were framed by HA (YPYDVPDYAG, 5 spots) and polio (YPYDVPDYAG, 3 spots) control peptides. Additionally, each sub-array was framed by glycine spacers (G spots).

## 204 3.7 Peptide microarrays immunoassay

Immunoassays were performed by PEPperPRINT GmbH (Heidelberg, Germany) as previously 205 206 described (26,27). Briefly, the immunoassays involved two steps on the same microarray. The preincubation step which was performed to identify false positive signals by binding of the fluorescent 207 labelled secondary antibody followed by the main incubation with serum and the secondary antibodies. 208 At each step there was pre-swelling of the peptide microarrays with washing buffer (PBS, pH 7.4 with 209 0.05% Tween 20) for 10 minutes. The peptide microarrays were scanned using an LI-COR Odyssey 210 Imaging System, scanning offset 0.65 mm, resolution 21  $\mu$ m, scanning intensities of 7/7 (red = 680 211 212 nm / green = 800 nm). To ensure that all microarrays were responding correctly, all steps were repeated with the Cy3-conjugated anti-HA control antibody and Cy3-conjugated anti-polio control antibodies. 213 214 Quantification of spot intensities was based on 16-bit gray scale tiff files. Microarray image analysis was done with PepSlide1 Analyzer and resulted in raw data CSV files for each sample (green = 800 215 nm = IgM staining, red = 680 nm = IgG staining). A PEPperPRINT software algorithm calculated 216 217 averaged median foreground intensities (foreground-background signal) and spot-to-spot deviations

of spot duplicates and assembled the outcome in summary files. For duplicate spots a maximum spotto-spot deviation of 50% was tolerated, otherwise the corresponding intensity value was zeroed.

220 **3.8** Identifying schistome-specific antigenic peptides.

The negative cut-off was determined by averaging the negative control readings (10 sera obtained 221 from schistosomiasis unexposed and uninfected individuals with no prior history of Schistosoma 222 223 infections) and adding 3 standard deviations. A positive response was defined as fluorescence intensity above the negative cut-off for each specific peptide for both IgG and IgM. Peptides for which at least 224 one infected individual was positive were selected for further analysis. Statistical comparison between 225 groups was done by the Kruskal-Wallis equality-of-populations rank test and *p-values* less 0.05 were 226 considered statistically significant. Diagnostic accuracy was evaluated by receiver operating 227 characteristic (ROC) curve analysis. The area under the ROC curve (AUC) was calculated to assess 228 the overall diagnostic performance of peptides that were able to distinguish schistosome positives from 229 230 schistosome negatives or healthy controls. Data curation and analyses were performed with Microsoft excel and Stata v17 (Stata, College Station, Texas, USA) respectively. 231

#### 232 4 Results

#### **233** 4.1 **Demographic and parasitology characteristics**

The case control diagnostic accuracy study consisted of 135 participants [62.96 % (85) females and 234 37.04 % (50) males] with a median age of 9 (IQR: 4-12) from Mashonaland central (92.59 %) a high 235 schistosomiasis endemic area (2) and Harare (7.41 %). Among the participants Mashonaland central 236 43 were confirmed to be infected with S. haematobium and 36 confirmed to be uninfected with S. 237 haematobium by the urine filtration technique (S1 file). For S. mansoni 46 were confirmed to be 238 239 infected and 37 were confirmed to be uninfected by the Kato Katz method and the formal ether concentration technique (S1 file). Ten participants without confirmed Schistosoma infections and 240 241 without a history of infection and contact with contaminated water were recruited from Glaudina a high density urban area located in Harare (S1 file). 242

## 4.2 Identification and characterisation *schistosome* recombinant proteins for novel peptides prediction.

Two recombinant proteins MS3\_10385 a serine protease inhibitor (SERPIN) and MS3\_10186 a tetraspanin were selected for *S. haematobium* based on their overall diagnostic performances (**Table 1**). The two proteins were predicted to have a signal peptide attached to them indicating they are utilised outside the cell. MS3\_10385 and MS3\_10186 were both predicted to be soluble proteins indicating that they are not part of the transmembrane helix. Finally, these two proteins were predicted to be part of the extracellular matrix where immunological reactions are likely to occur.

### 251 Table 1: Properties and characteristics S. haematobium and S. mansoni recombinant proteins

Description	Protein family	Gene name	Accession Source number organism		Signal peptide	Transmembra ne helix	Cellular localisation
Neuroserpin	SERPIN	MS3_10385	A0A095A7Z5	S. haematobium	Signal peptide cleavage site position 27 and 28	Soluble protein	Extracellular membrane
IPSE	Tetraspanin	MS3_10186	A0A095A2X3	S. haematobium	Signal peptide cleavage site position 20 and 21	Soluble protein	Extracellular membrane
RP26	SAPLIP	AAB81008	Q26536	S. mansoni	Signal peptide cleavage site position 18 and 19	Membrane protein	Extracellular membrane
SmSPI	SERPIN	SmSPI	G4LYU6	S. mansoni	Not signal peptide	Soluble protein	Mitochondria

252 Saposin-like proteins (SAPLIP)

253 Serine protease inhibitor (SERPIN)

For *S. mansoni* one protein AAB81008 a saposin-like protein (SAPLIP) was selected based on the based overall diagnostic criteria. However, the second protein SmSPI a SERPIN was selected due to its ability to detect early schistosome infections (28) and its potential to detect single worm infections. AAB81008 was predicted to have a signal peptide attached to it and SmSPI was predicted not to possess a signal peptide. AAB81008 was predicted to be a membrane protein and SMSPI was predicted to be a soluble protein. AAB81008 was predicted to be part of the extracellular matrix. SmSPI was predicted to be located in the mitochondria.

#### 261 4.3 Linear B-cell epitopes/peptides

- From the 122 peptides *S. haematobium* and *S. mansoni* peptides 40.98 % (n=50) were predicted with
- ABCpred, 22.95 % (n=28) with Bepi Pred 2, 21.31 % (n=26) and the remaining 14.75 % (n=18) were
- obtained from literature (S2 file). Tables 2 and 3 shows that from the 122 peptides, only 15.57 %
- were able to distinguish schistosome positives from schistosome negatives or healthy controls.

Peptide name	Linear sequence	Source	Antibody	Reference	p-value	ROC	Std.erro	95 % Confidence interval		Peptide
		organism				AUC	r	Lower limit	Upper limit	prediction and selection
MS3_10186-119-35	VQCISESKRRRKYCRY	S. haematobium	IgG	S. mansoni negative	0.0328	0.6516	0.0607	0.53259	0.77058	ABCpred
				Healthy controls		0.6772	0.0796	0.52116	0.83319	
MS3_10186-123-131	SESKRRRKY	S. haematobium	IgG	S. mansoni negative	0.011	0.6219	0.0612	0.50202	0.74182	Bepi Pred 2
				Healthy controls		0.7690	0.0656	0.64093	0.89820	
MS3_10385-278-291	SIGVVDLFDPVKSD	S. haematobium	IgG	S. mansoni negative	0.0274	0.6475	0.0612	0.52755	0.76740	Bcepred
				Healthy controls		0.6924	0.0989	0.49858	0.88620	-
MS3_10385-339-354	VDFHVTHPFICFIYDQ	S. haematobium	IgG	S. mansoni negative	0.0207	0.6301	0.0613	0.51002	0.75027	Bcepred
				Healthy controls		0.7261	0.0917	0.54641	0.90576	
SmSPI-177-193	MDDIPDDTGMILVNVF	S. mansoni	IgG	S. mansoni negative	0.0113	0.6539	0.0610	0.5344	0.77241	ABCpred
				Healthy controls		0.7239	0.0852	0.55700	0.89083	
SmSPI-378-388	NHPFICFIYDQ	S. mansoni	IgG	S. mansoni negative	0.01	0.6392	0.0612	0.51923	0.75926	Bcepred
				Healthy controls		0.7663	0.0834	0.602	0.92967	
SmSPI-362-378	IFVPISAVLPDIDFNV	S. mansoni	IgG	S. mansoni negative	0.0287	0.6486	0.0607	0.52965	0.76764	ABCpred
				Healthy controls		0.6957	0.0975	0.50460	0.88670	
AAB81008-19-30	INQPELEFGYKD	S. mansoni	IgG	S. mansoni negative	0.0019	0.6531	0.0599	0.53559	0.77052	Bepi Pred 2
				Healthy controls		0.8043	0.0660	0.67495	0.93374	
SmSP1-310-323	LKSMGIVDLFNPVA	S. mansoni	IgG	S. mansoni negative	0.0149	0.6525	0.0565	0.54170	0.77052	Bepi Pred 2
				Healthy controls		0.4402	0.0872	0.262929	0.61114	
SmSP1_359_372	TSPIFVPISAVLPD	S. mansoni	IgG	S. mansoni negative	0.004	0.7124	0.0560	0.60261	0.82218	Bepi Pred 2
				Healthy controls		0.5565	0.1083	0.34418	0.76887	
Smp 126160-438-452	LVTPESKYYSSLPGN	S. mansoni	IgG	S. mansoni negative	0.0022	0.7156	0.0559	0.605	0.82218	Published
				Healthy controls		0.6761	0.0921	0.49562	0.85656	
MS3_10186-25-41	YCLRLYDGTYENGSYT	S. haematobium	IgG	S. mansoni negative	0.0035	0.7115	0.0580	0.59781	0.82522	ABCpred
				Healthy controls		0.6478	0.0970	0.4563	0.83802	
MS3_10186-40-49	PGSVCVPLIH	S. haematobium	IgG	S. mansoni negative	0.015	0.6604	0.0496	0.56315	0.75765	Bcepred
				Healthy controls		0.7098	0.0500	0.61173	0.80784	
AAB81008-181-196	STMDPDSACMTMHMCS	S. mansoni	IgG	S. mansoni negative	0.0226	0.6710	0.0593	0.55466	0.78729	ABCpred
				Healthy controls		0.5304	0.0987	0.33693	0.72394	
SmSPI-197-214	FWESPFEPHYTKIENFDI	S. mansoni	IgG	S. mansoni negative	0.05	0.5793	0.0643	0.45339	0.70525	Bepi Pred 2
				Healthy controls		0.7326	0.0775	0.58073	0.88448	
Smp 150390.1-216-230	SLPSNAHNNDNNSSD	S. mansoni	IgG	S. mansoni negative	0.0131	0.6713	0.0608	0.55217	0.79037	Published
				Healthy controls		0.6989	0.0874	0.52761	0.87022	
MS3_10186-105-121	ISS1QKCVYGENGMVQ	S. haematobium	IgM	S. mansoni negative	0.0123	0.6898	0.0593	0.57352	0.80604	ABCpred
				Healthy controls		0.602	0.1067	0.46754	0.7501	
MS3_10186-40-49	PGSVCVPLIH	S. haematobium	IgM	S. mansoni negative	0.0158	0.6387	0.0582	0.52379	0.75353	Bcepred
				Healthy controls		0.7413	0.0644	0.61628	0.85607	

#### 266 Table 2. Diagnostic performance of peptides for *S. mansoni* IgG and IgM detection.

267 The peptide name was derived from the gene name followed by the position of the peptide amino acid sequence on the protein.

p-values were determined by the Kruskal-Wallis equality-of-populations rank test and p-values less than 0.05 were considered significant.

## 270 Table 3. Diagnostic performance of peptides for *S. haematobium* IgG and IgM detection.

Peptide name	Linear sequence	Source	Antibody	Reference	p-value	ROC	Std.erro	Confidence interval		Peptide
		organism				AUC	r	Lower limit	Upper limit	prediction
										and selection
SmSPI-177-193	MDDIPDDTGMILVNVF	S. mansoni	IgG	S. haematobium negative	0.032	0.372	0.0647	0.24602	0.49946	ABCpred
				Healthy controls		0.6302	0.1065	0.42153	0.83894	
AAB81008-19-30	INQPELEFGYKD	S. mansoni	IgG	S. haematobium negative	0.0384	0.4464	0.0666	0.31587	0.57690	Bepi Pred 2
				Healthy controls		0.7326	0.0810	0.5786	0.8916	
SmSP1-165-181	DQQSNGLLEKFFMDDIP	S. mansoni	IgG	S. haematobium negative	0.0373	0.4092	0.0650	0.28180	0.53668	Bepi Pred 2
				Healthy controls		0.6674	0.1017	0.46811	0.86678	
AAB81008-19-30	INQPELEFGYKD	S. mansoni	IgM	S. haematobium negative	0.0294	0.3692	0.0640	0.24367	0.49470	Bepi Pred 2
				Healthy controls		0.6116	0.1053	0.40522	0.81804	

The peptide name was derived from the gene name followed by the position of the peptide amino acid sequence on the protein.

272

p-values were determined by the Kruskal-Wallis equality-of-populations rank test and p-values less than 0.05 were considered significant.

## **4.4 Diagnostic performance for discriminating** *S. mansoni* **positives from healthy controls.**

- Out of the 16 peptides that were able to distinguish S. mansoni positive sera from schistosome 276 277 negative or healthy controls sera, only peptide AA81008-19-30 had an excellent diagnostic performance for discriminating S. mansoni positives from healthy controls with an AUC value 278 279 of 0.8043 for IgG peptide microarray (Fig 1). Six peptides MS3 10186-123-131, MS3 10385-339-354, SmSPI-177-193, SmSPI-379-388, MS3-10186-40-49 and SmS-197-214 had 280 acceptable diagnostic performances for discriminating S. mansoni positives from healthy 281 controls with AUC values ranging from 0.7098 to 0.7763 for IgG peptide microarray (S3 file). 282 For IgM peptide microarray the ROC curve analysis for discriminating S. mansoni positives 283 from the healthy controls yielded AUC values of 0.602 and 0.7413 for MS3 10186-105-121 284 and MS3 10186-40-49 respectively (S3 file). Peptide MS3 10186-40-49 had acceptable 285 diagnostic performances for discriminating S. mansoni positives from healthy controls for both 286 IgG and IgM (Fig 2). 287
- Fig 1: Diagnostic performance for Peptide AAB81008-19-30 a. Peptide AAB81008-19-30
  receiver operating characteristic (ROC) curve and area under the ROC curve (AUC) for
  discrimination of *S. mansoni* positives from healthy controls for IgG. b. Peptide AAB8100819-30 receiver operating characteristic (ROC) curve and area under the ROC curve (AUC) for
  discrimination of *S. mansoni* positives from healthy controls for IgG.

Fig 2: Diagnostic performance for Peptide MS3 10186-40-49 a. Peptide MS3 10186-40-49
receiver operating characteristic (ROC) curve and area under the ROC curve (AUC) for
discrimination of *S. mansoni* positives from healthy controls for IgG. b. Peptide MS3 1018640-49 receiver operating characteristic (ROC) curve and area under the ROC curve (AUC) for
discrimination of *S. haematobium* positives from healthy controls for IgM.

## 4.5 Diagnostic performance for discriminating *S. mansoni* positives from *S. mansoni* negatives.

- 300 Three peptides SmSPI-359-372, Smp126160-438-452 and MS3 10186-25-41 had acceptable
- 301 diagnostic performances for discriminating S. mansoni positives from S. mansoni negatives
- with AUC values of 0.7124, 0.7156, 0.7115 respectively for IgG peptide microarray (fig 3).
- 303 For IgM peptide microarray the ROC curve analysis for discriminating the *S. mansoni* positives

from the S. mansoni negatives yielded AUC values of 0.6898 and 0.6387 for MS3 10186-105-

305 121 and MS3 10186-40-49 respectively (S3 file).

Fig 3: IgG receiver operating characteristic (ROC) curves and area under the ROC curves
(AUC) for discriminating *S. mansoni* positives from *S. mansoni* negatives for IgG peptide
microarray. a. Peptide SmpSPI-359-372 b. Peptide Smp126160-438-452 c. Peptide MS3
10186-25-41

## 310 4.6 Diagnostic performance for discriminating *S. haematobium* positives from *S. haematobium* negatives and healthy controls.

The four peptides that were able to distinguish S. haematobium positives from S. haematobium 312 313 negatives or healthy controls had inaccurate diagnostic performances for discriminating S. haematobium positives from S. haematobium negatives for both IgG and IgM peptide 314 microarray (S4 file). Peptides SmSPI-177-193 and SmSPI-165-181 had poor diagnostic 315 performances for discriminating S. haematobium positives from healthy controls for IgG 316 peptide microarray. Peptide AAB81008 had an acceptable diagnostic performance for 317 discriminating S. haematobium positives from healthy controls with an AUC value of 0.7326 318 for IgG peptide microarray. Peptide AAB81008 was able to discriminate both S. haematobium 319 and S. mansoni positives from healthy controls (Fig 1). 320

## **4.7** Spatial location of novel peptides with good and acceptable diagnostic

### 322 performance on the recombinant proteins 3D structures.

Understanding the spatial location of peptides within a protein crystal structure is crucial for unravelling the intricacies of molecular interactions and biological functions. In our study DeepView/Swiss-PDB Viewer (www.expasy.org/spdbv/) was used for spatial location of the candidate peptides on the protein crystal structure of recombinant proteins (MS3\_10385; MS3\_10186; AAB81008 and SmSPI) (**Fig 4**). Peptides AAB1008-19-30, MS3\_10186-123-131 and MS3\_10385-339-354 were located at the exterior surface of their respective protein structures. Most of the target peptide amino acid sequence was located at the exterior surface

of the protein with a few amino acid residues encapsulated within the protein for peptides SmSPI\_359-372 and MS3\_10186-2541. Lastly, most of the amino acid residues for peptides for SmSPI\_177-193, SmSPI\_378-388, MS3\_10186-40-49 and SmSPI-197-214 were encapsulated within the protein structure and only a few amino acid residues were at the exterior surface of the protein.

Fig 4: Spatial location of novel peptides with good and acceptable diagnostic performances on
the recombinant proteins 3D structures. DeepView/Swiss-PDB Viewer was used to determine
the spatial location of the peptides on the crystal structure of recombinant proteins
(MS3\_10385; MS3\_10186; AAB81008 and SmSPI).

## 339 **5 Discussion**

As countries target the elimination of schistosomiasis as a public health problem and as the 340 prevalence of the disease decreases due to MDA campaigns, it has become apparently clear 341 that more sensitive field-applicable diagnostics are needed for the effective management and 342 343 surveillance of schistosome infections as advocated by the WHO (29–31). This is particularly important in low endemicity areas, where microscope-based diagnostic methods may 344 345 underestimate the true prevalence of the disease (11,32). This background has provided an 346 impetus for this study in the identification of peptides that can be employed in the development of antibody-based diagnostic tools using an immunoinformatic approach and peptide 347 microarray immunoassay validation. 348

Carvalho and colleagues, 2022 and Lopes and colleagues, 2017 had previously used immunoinformatic approaches and immune-assay validation to identify *S. haematobium* and *S. mansoni* peptides with diagnostic potential (18,19). This study identified one peptide (AA81008-19-30) that had an excellent diagnostic performance for discriminating *S. mansoni* positives from healthy controls for IgG. Six peptides that had acceptable diagnostic performances for discriminating *S. mansoni* positives from healthy controls were identified for IgG. For discriminating *S. mansoni* positives from *S. mansoni* negatives three peptides were

identified for IgG. Peptide AAB81008 was shown to have an acceptable diagnostic
performance for discriminating *S. haematobium* positives from *S. haematobium* negatives.
Peptide AAB81008 was able to discriminate both *S. haematobium* and *S. mansoni* positives
from healthy controls.

Eighteen previously published peptides were included on the peptide microarray, 10 from our 360 previous study Vengesai and colleagues, 2022 (26) and 8 peptides from two studies by 361 Carvalho and Colleagues, 2022 and Lopes and Colleagues, 2017 (18,19). Despite Carvalho 362 and Colleagues, 2022 and Lopes and Colleagues, 2017 showing that peptides Sm168240, 363 Smp 136560 (1564 - 1578),Smp 126160(438-452), Sm140560, Sm041370, 364 Smp 180240(339-353), Smp 150390.1(216-230), Smp 093840(219-233) had AUC values 365 ranging from 0.76 (95 % CI 0.6024-0.9213) to 0.99 (95 % CI 0.987-100) results from this 366 current study show that only one published peptide Smp 126160-438-452 had an acceptable 367 diagnostic performance with an AUC value of 0.7115 (95% CI 0.605-0.82218). The findings 368 may be attributed to the fact that peptide microarray immunoassays were used in the 369 determination of antibody reactivity against the peptides whilst in other two studies (18,19) 370 antibody reactivity was investigated using peptide based serum IgG ELISA. Pertaining the 371 other 10 published peptides XP 035587815.1-269-283, XP 012797374.1-78-92, 372 AAZ29530.1-25-29, XP 012799745.1-16-30, P20287.1-58-72, AAA29903.1-222-237, 373 P09841.3-6-20, AAA29900.1-145-159, P09792.1-29-43, XP 035588858.1-206-220 none of 374 them showed a clear discrimination between the schistosome infected and uninfected groups 375 and these results are in agreement with findings from our previous study (26). 376

377 5.1 Limitations and recommendations

Ideally, to properly evaluate the performance of the identified peptides their diagnosticaccuracy need to be compared to a reference standard test. The reference standard test should

17

be able to discriminate the true positives and true negatives. The absence of a standard reference 380 test or absolute knowledge of the true positives was a significant limitation in the present study 381 (11,33,34). Despite the inappropriateness of doing so, Kato-Katz and urine filtration techniques 382 were used as the reference tests in the current study. The techniques lack sensitivity especially 383 in low endemicity settings; hence it is expected that some positive individuals were 384 misdiagnosed as false-negative (10,11). This might have contributed to the low diagnostic 385 386 performances of the some identified peptides. To circumvent this limitation, we propose use of the latent class analysis previously described by Mesquita and colleagues, 2022, which 387 388 combines multiple test results to construct a standard reference outcome (11).

Unfortunately, like most currently available serological tests the peptides identified are not 389 useful for monitoring and evaluation programmes because antibodies to schistosome infections 390 remain detectable long after treatment (35). This limits the clinical value of antibody detection 391 for confirmation of the success of chemotherapy since specific antibodies continue to be 392 present long after the worms have disappeared (14,36). There may be certain antigens (for 393 example peptides) to which certain antibody isotype subclasses like IgG<sub>4</sub>, disappear more 394 rapidly (35). These antibodies can be targeted to circumvent the limitation associated with 395 396 persisting antibodies. According to the WHO, serological and immunological tests are useful for showing exposure to schistosome infection in people living in non-endemic or low-397 398 transmission (37). Alternatively, the identified peptides can be used to develop serological tools for showing exposure to infection for people living in non-endemic and low-transmission areas. 399

As urogenital and intestinal schistosomiasis are poverty related diseases prevalent in resourcelimited settings, cost is a major factor for developing diagnostics for the disease (38). The peptide microarray technology described in this study is too complex and expensive for routine clinical microbiology in resource-limited settings. There it is recommend that the peptides discovered be transferred to a wide range of platforms including, enzyme-linked

immunosorbent assay, lateral flow, western blot, and bead-based assays, where they may
experdite diagnostics, epidemiology and vaccinology.

#### 407 **5.2** Conclusion

In conclusion, 1 peptide with a good diagnostic performance and 9 peptides with acceptable 408 diagnostic performance were identified using the immunoinformatic approach and peptide 409 microarray validation. Identified peptides maybe be used to develop diagnostic tools for 410 showing exposure to schistosome infection in people living in non-endemic or low-411 transmission areas. Peptides SmPI-177-198 and SmSPI-379-388 may be used to develop a 412 chimeric protein for diagnosis of early S. mansoni and single worm infections. However, there 413 is need for validation of the findings with true negative controls from a non-endemic country 414 and a good reference tool. 415

## 416 6 Acknowledgments

We thank the communities of Shamva, and Mount Darwin rural districts in the Mashonaland
Central province of Zimbabwe for their participation, and support in the study. The authors
would like to acknowledge the valuable input of laboratory technicians from the University of
Zimbabwe who assisted in sample collection.

#### 421 7 References

- 422 1. Schistosomiasis [Internet]. [cited 2023 May 24]. Available from:
  423 https://www.who.int/news-room/fact-sheets/detail/schistosomiasis
- Midzi N, Mduluza T, Chimbari MJ, Tshuma C, Charimari L, Mhlanga G, et al. Distribution of Schistosomiasis and Soil Transmitted Helminthiasis in Zimbabwe: Towards a National Plan of Action for Control and Elimination. Kabatereine NB, editor.
   PLoS Negl Trop Dis [Internet]. 2014 Aug 14 [cited 2020 Mar 3];8(8):e3014. Available from: http://dx.plos.org/10.1371/journal.pntd.0003014
- 3. Nausch N, Dawson EM, Midzi N, Mduluza T, Mutapi F, Doenhoff MJ. Field evaluation of a new antibody-based diagnostic for Schistosoma haematobium and S. mansoni at the point-of-care in northeast Zimbabwe [Internet]. 2014 [cited 2020 May 20]. Available from: http://www.biomedcentral.com/1471-2334/14/165
- 4. Vengesai A, Naicker T, Kasambala M, Midzi H, Mduluza-Jokonya T, Rusakaniko S, et
  al. Clinical utility of peptide microarrays in the serodiagnosis of neglected tropical

diseases in sub-Saharan Africa: protocol for a diagnostic test accuracy systematic 435 review. 2021 Jul [cited] 2022 Jan 9];11(7):e042279. Available from: 436 https://pubmed.ncbi.nlm.nih.gov/34330850/ 437

- 5. Archer J, Barksby R, Pennance T, Rostron P, Bakar F, Knopp S, et al. Analytical and 438 439 Clinical Assessment of a Portable, Isothermal Recombinase Polymerase Amplification (RPA) Assay for the Molecular Diagnosis of Urogenital Schistosomiasis. Mol 2020, Vol 440 25, Page 4175 [Internet]. 2020 Sep 11 [cited 2023 May 24];25(18):4175. Available 441 from: https://www.mdpi.com/1420-3049/25/18/4175/htm 442
- 6. Lim MD, Brooker SJ, Belizario VY, Gay-Andrieu F, Gilleard J, Levecke B, et al. 443 Diagnostic tools for soil-transmitted helminths control and elimination programs: A 444 pathway for diagnostic product development. PLoS Negl Trop Dis [Internet]. 2018 Mar 445 [cited 2023 Mav 24]:12(3):e0006213. Available 446 1 from: https://journals.plos.org/plosntds/article?id=10.1371/journal.pntd.0006213 447
- Mu Y, Gordon CA, Olveda RM, Ross AG, Olveda DU, Marsh JM, et al. Identification 7. 448 of a linear B-cell epitope on the Schistosoma japonicum saposin protein, SjSAP4: 449 Potential as a component of a multi-epitope diagnostic assay. PLoS Negl Trop Dis 450 24];16(7):e0010619. [Internet]. 2022 [cited 2023 May Available from: 451 https://journals.plos.org/plosntds/article?id=10.1371/journal.pntd.0010619 452
- Hoermann J, Kuenzli E, Schaefer C, Paris DH, Bühler S, Odermatt P, et al. Performance 453 8. of a rapid immuno-chromatographic test (Schistosoma ICT IgG-IgM) for detecting 454 Schistosoma-specific antibodies in sera of endemic and non-endemic populations. PLoS 455 Negl Trop Dis [Internet]. 2022 [cited 2023 May 24];16(5):e0010463. Available from: 456 https://journals.plos.org/plosntds/article?id=10.1371/journal.pntd.0010463 457
- Menezes DL, Santos CT de J, Oliveira YLDC, Campos VTC, Negrão-Corrêa DA, 9. 458 Geiger SM, et al. Accuracy Study of Kato-Katz and Helmintex Methods for Diagnosis 459 of Schistosomiasis Mansoni in a Moderate Endemicity Area in Sergipe, Northeastern 460 Brazil. Diagnostics 2023, Vol 13, Page 527 [Internet]. 2023 Jan 31 [cited 2023 May 461 24];13(3):527. Available from: https://www.mdpi.com/2075-4418/13/3/527/htm 462
- 463 10. Colley DG, King CH, Kittur N, Ramzy RMR, Secor WE, Fredericks-James M, et al. Evaluation, Validation, and Recognition of the Point-of-Care Circulating Cathodic 464 Antigen, Urine-Based Assay for Mapping Schistosoma mansoni Infections. Am J Trop 465 Med Hyg [Internet]. 2020 May 12 [cited 2023 May 24];103(1 Suppl):42–9. Available 466 from: https://www.ajtmh.org/view/journals/tpmd/103/1 Suppl/article-p42.xml 467
- Mesquita SG, Caldeira RL, Favre TC, Massara CL, Beck LCNH, Simões TC, et al. 11. 468 Assessment of the accuracy of 11 different diagnostic tests for the detection of 469 Schistosomiasis mansoni in individuals from a Brazilian area of low endemicity using 470 latent class analysis. Front Microbiol. 2022 Dec 15;13:4683. 471
- Pearson MS, Tedla BA, Mekonnen GG, Proietti C, Becker L, Nakajima R, et al. 472 12. Immunomics-guided discovery of serum and urine antibodies for diagnosing urogenital 473 schistosomiasis: a biomarker identification study. The Lancet Microbe [Internet]. 2021 474 26];2(11):e617–26. Nov 1 [cited 2023 May Available from: 475 http://www.thelancet.com/article/S2666524721001506/fulltext 476
- Imai N, Rujeni N, Nausch N, Bourke CD, Appleby LJ, Cowan G, et al. Exposure, 477 13. infection, systemic cytokine levels and antibody responses in young children 478 concurrently exposed to schistosomiasis and malaria. Parasitology. 479 2011

medRxiv preprint doi: https://doi.org/10.1101/2023.12.28.23300599; this version posted December 29, 2023. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in

perpetuity. It is made available under a CC-BY 4.0 International license .

#### Oct;138(12):1519-33. 480

- 14. Ogongo P, Kariuki TM, Wilson RA. Diagnosis of schistosomiasis mansoni: an 481 evaluation of existing methods and research towards single worm pair detection. 482 Parasitology [Internet]. 2018 Sep 1 [cited 2022 Mar 12];145(11):1355-66. Available 483 from: https://www.cambridge.org/core/journals/parasitology/article/abs/diagnosis-of-484 schistosomiasis-mansoni-an-evaluation-of-existing-methods-and-research-towards-485 single-worm-pair-detection/552001BF61F171FB60F11577DC42280A 486
- 487 15. Ma L, Zhao W, Hou X, Liu M, Li Y, Shen L, et al. Identification of linear epitopes in SjSP-13 of Schistosoma japonicum using a GST-peptide fusion protein microplate 488 array. Parasites and Vectors [Internet]. 2019 Oct 30 [cited 2020 Nov 22];12(1). 489 Available from: https://pubmed-ncbi-nlm-nih-gov.ukzn.idm.oclc.org/31666115/ 490
- 16. Falconi-Agapito F, Kerkhof K, Merino X, Bakokimi D, Torres F, Van Esbroeck M, et 491 al. Peptide Biomarkers for the Diagnosis of Dengue Infection. Front Immunol. 2022 Jan 492 26:13:52. 493
- 17. de Oliveira EJ, Kanamura HY, Takei K, Hirata RDC, Valli LCP, Nguyen NY, et al. 494 Synthetic peptides as an antigenic base in an ELISA for laboratory diagnosis of 495 schistosomiasis mansoni. Trans R Soc Trop Med Hyg [Internet]. 2008 Apr 1 [cited 2022] 496 Feb 15];102(4):360–6. Available from: https://pubmed.ncbi.nlm.nih.gov/18314149/ 497
- 498 18. Carvalho GBF, Resende DM, Sigueira LMV, Lopes MD, Lopes DO, Coelho PMZ, et al. Selecting targets for the diagnosis of Schistosoma mansoni infection: An integrative 499 approach using multi-omic and immunoinformatics data. PLoS One [Internet]. 2017 500 Aug 1 [cited] 2022 Jan 9];12(8):e0182299. Available from: 501 https://journals.plos.org/plosone/article?id=10.1371/journal.pone.0182299 502
- Lopes MD, Oliveira FM, Coelho IEV, Passos MJF, Alves CC, Taranto AG, et al. 503 19. Epitopes rationally selected through computational analyses induce T-cell proliferation 504 505 in mice and are recognized by serum from individuals infected with Schistosoma mansoni. Biotechnol Prog [Internet]. 2017 May 1 [cited 2022 Feb 14];33(3):804-14. 506 507 Available from: https://pubmed.ncbi.nlm.nih.gov/28371522/
- 20. Van Regenmortel MHV. Structural and functional approaches to the study of protein 508 antigenicity [Internet]. Vol. 10, Immunology Today, Immunol Today; 1989 [cited 2021] 509 Jun 14]. p. 266–72. Available from: https://pubmed.ncbi.nlm.nih.gov/2478146/ 510
- 21. Giacò L, Amicosante M, Fraziano M, Gherardini PF, Ausiello G, Helmer-Citterich M, 511 et al. B-Pred, a structure based B-cell epitopes prediction server. Adv Appl Bioinforma 512 Chem [Internet]. 2012 Jul 25 [cited 2021 Jun 14];5(1):11-21. Available from: 513 http://dx.doi.org/10.2147/AABC.S30620 514
- 22. Vengesai A, Kasambala M, Mutandadzi H, Mduluza-Jokonyaid TL, Mduluzaid T, 515 Naicker T, et al. Scoping review of the applications of peptide microarrays on the fight 516 against human infections. PLoS One [Internet]. 2022 Jan [cited 2022 Feb 517 13];17(1):e0248666. Available from: 518 https://journals.plos.org/plosone/article?id=10.1371/journal.pone.0248666 519
- Sanchez-Lockhart M, Reyes DS, Gonzalez JC, Garcia KY, Villa EC, Pfeffer BP, et al. 23. 520 Qualitative Profiling of the Humoral Immune Response Elicited by rVSV- $\Delta$ G-EBOV-521 522 GP Using a Systems Serology Assay, Domain Programmable Arrays. Cell Rep [Internet]. 2018 Jul 24 [cited 2020 Nov 26];24(4):1050-1059.e5. Available from: 523

- https://doi.org/10.1016/j.celrep.2018.06.077 524
- 525 24. Sanchez-Trincado JL, Gomez-Perosanz M, Reche PA. Fundamentals and Methods for T- and B-Cell Epitope Prediction [Internet]. Vol. 2017, Journal of Immunology 526 Research. Hindawi Limited; 2017 [cited 2021 Jan 14]. Available from: 527 https://pubmed.ncbi.nlm.nih.gov/29445754/ 528
- 25. Vengesai A, Muleya V, Midzi H, Tinago TV, Chipako I, Manuwa M, et al. Diagnostic 529 performances of Schistosoma haematobium and Schistosoma mansoni recombinant 530 531 proteins, peptides and chimeric proteins antibody based tests. Systematic scoping review. PLoS One. 2023 Mar 1;18(3 March). 532
- 26. Vengesai A, Naicker T, Midzi H, Kasambala M, Mduluza-Jokonya TL, Rusakaniko S, 533 et al. Multiplex peptide microarray profiling of antibody reactivity against neglected 534 tropical diseases derived B-cell epitopes for serodiagnosis in Zimbabwe. PLoS One 535 [Internet]. 2022 Jul 1 [cited 2023 Jan 31];17(7):e0271916. Available from: 536 https://journals.plos.org/plosone/article?id=10.1371/journal.pone.0271916 537
- 27. Vengesai A, Naicker T, Midzi H, Kasambala M, Muleya V, Chipako I, et al. Peptide 538 microarray analysis of in-silico predicted B-cell epitopes in SARS-CoV-2 sero-positive 539 healthcare workers in Bulawayo, Zimbabwe. Acta Trop [Internet]. 2023 Feb 1 [cited 540 2023 31]:238:106781. Available from: 541 Jan https://linkinghub.elsevier.com/retrieve/pii/S0001706X22004727 542
- 28. Tanigawa C, Fujii Y, Miura M, Nzou SM, Mwangi AW, Nagi S, et al. Species-Specific 543 Serological Detection for Schistosomiasis by Serine Protease Inhibitor (SERPIN) in 544 545 Multiplex Assay. PLoS Negl Trop Dis [Internet]. 2015 [cited 2020 May 201:9(8):e0004021. Available from: 546
- https://journals.plos.org/plosntds/article?id=10.1371/journal.pntd.0004021 547
- 29. Colley DG, King CH, Kittur N, Ramzy RMR, Secor WE, Fredericks-James M, et al. 548 549 Evaluation, Validation, and Recognition of the Point-of-Care Circulating Cathodic Antigen, Urine-Based Assay for Mapping Schistosoma mansoni Infections. Am J Trop 550 Med Hyg [Internet]. 2020 May 12 [cited 2023 Dec 4];103(1 Suppl):42–9. Available 551 from: https://www.ajtmh.org/view/journals/tpmd/103/1 Suppl/article-p42.xml 552
- Archer J, Barksby R, Pennance T, Rostron P, Bakar F, Knopp S, et al. Analytical and 30. 553 Clinical Assessment of a Portable, Isothermal Recombinase Polymerase Amplification 554 (RPA) Assay for the Molecular Diagnosis of Urogenital Schistosomiasis. Mol 2020, Vol 555 25, Page 4175 [Internet]. 2020 Sep 11 [cited 2023 Dec 4];25(18):4175. Available from: 556 https://www.mdpi.com/1420-3049/25/18/4175/htm 557
- Pearson MS, Tedla BA, Mekonnen GG, Proietti C, Becker L, Nakajima R, et al. 31. 558 Immunomics-guided discovery of serum and urine antibodies for diagnosing urogenital 559 schistosomiasis: a biomarker identification study. The Lancet Microbe [Internet]. 2021 560 Nov [cited 2022 Feb 14];2(11):e617–26. from: 561 1 Available http://www.thelancet.com/article/S2666524721001506/fulltext 562
- Nausch N, Dawson EM, Midzi N, Mduluza T, Mutapi F, Doenhoff MJ. Field evaluation 563 32. of a new antibody-based diagnostic for Schistosoma haematobium and S. mansoni at the 564 point-of-care in northeast Zimbabwe. BMC Infect Dis [Internet]. 2014 Mar 26 [cited 565 27];14(1):1-9. 566 2023 Mav Available from: https://bmcinfectdis.biomedcentral.com/articles/10.1186/1471-2334-14-165 567

medRxiv preprint doi: https://doi.org/10.1101/2023.12.28.23300599; this version posted December 29, 2023. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in

perpetuity. It is made available under a CC-BY 4.0 International license .

- 33. Torlakovic EE, Francis G, Garratt J, Gilks B, Hyjek E, Ibrahim M, et al. Standardization 568 of negative controls in diagnostic immunohistochemistry: Recommendations from the 569 international Ad Hoc expert panel. Appl Immunohistochem Mol Morphol [Internet]. 570 2014 [cited] 2022 Mav 10];22(4):241-52. Available 571 from: https://journals.lww.com/appliedimmunohist/Fulltext/2014/04000/Standardization of 572 Negative Controls in Diagnostic.1.aspx 573
- 34. West R, Kobokovich A. Understanding the Accuracy of Diagnostic and Serology Tests: 574 575 Sensitivity and Specificity Factsheet. 2020;
- 35. Diagnostic target product profiles for monitoring, evaluation and surveillance of 576 schistosomiasis control programmes [Internet]. [cited 2022 Jan 28]. Available from: 577 https://www.who.int/publications/i/item/9789240031104 578
- 36. Ogongo P. Identification and evaluation of Schistosoma mansoni proteins as diagnostic 579 targets for schistosomiasis. Int J Infect Dis. 2014 Apr 1;21:365. 580
- 37. Schistosomiasis [Internet]. [cited 2023 Dec Available from: 581 41. https://www.who.int/news-room/fact-sheets/detail/schistosomiasis 582
- Rivera J, Mu Y, Gordon CA, Jones MK, Cheng G, Cai P. Current and upcoming point-583 38. of-care diagnostics for schistosomiasis. Trends Parasitol [Internet]. 2023 Nov 23 [cited 584 585 2023 Dec 4]; Available from: 586 https://linkinghub.elsevier.com/retrieve/pii/S1471492223002805
- **Supplementary files** 8 587

#### S1 file 588

#### Excel file 589

- S. haematobium and S. mansoni demographics and parasitology and peptide microarray 590 immunoassay data sets. 591
- 592
- S2 file 593
- Excel file 594
- S. haematobium and S. mansoni linear B-cell epitopes 595
- 596

#### S3 file 597

- Word document 598
- 599 Receiver operating characteristics (ROC) curve and area under the ROC curve (AUC) for
- discrimination of S. mansoni positives from healthy controls and S. mansoni negatives. 600
- 601
- S4 file 602
- Word document 603
- Receiver operating characteristics (ROC) curve and area under the ROC curve (AUC) for 604 605 discrimination of S. haematobium positives from healthy controls and S. haematobium negatives. 606
- 607
- 608
- 609
- 610
- 611
- 612







